Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Levalbuterol Clear all
Completed Phase 3 Interventional Results available

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

NCT00400153
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
87
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT00665600
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Levalbuterol HCl, Albuterol Sulfate, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years to 99 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
20
States / cities
Carmichael, California • Spring Valley, California • Wheat Ridge, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

NCT05363670
View directory record Official record
Conditions
Asthma
Interventions
ARS-1 1 mg, Albuterol MDI, Placebo, ARS-1 2mg
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Tampa, Florida • Chevy Chase, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 4 Interventional

Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate

NCT00102882
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, salmeterol xinafoate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
86
States / cities
Mobile, Alabama • Little Rock, Arkansas • Fresno, California + 70 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00624286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
118
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

NCT00355342
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
37
States / cities
Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Not applicable Interventional Results available

Digihaler in Chronic Obstructive Pulmonary Disease (COPD)

NCT05241288
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Albuterol eMDPI DS
Combination Product
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 24, 2026, 10:44 AM EDT
Not listed Phase 1 Interventional

Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI

NCT01355991
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial

NCT02061280
View directory record Official record
Conditions
Asthma
Interventions
fluticasone/salmeterol 250/50 Dry Powder Inhaler, fluticasone/salmeterol 100/50 Dry Powder Inhaler, fluticasone 100mcg Dry Powder Inhaler
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 24, 2026, 10:44 AM EDT
Completed No phase listed Observational

Genetic Influences of Albuterol Response In Children With Bronchiolitis

NCT00570297
View directory record Official record
Conditions
Bronchiolitis
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
Up to 2 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 24, 2026, 10:44 AM EDT
Terminated Phase 3 Interventional

4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma

NCT00634517
View directory record Official record
Conditions
Asthma
Interventions
Armstrong Albuterol Sulfate Inhalation Aerosol, Albuterol Sulfate Inhalation Aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Long Beach, California • San Diego, California • Stockton, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 24, 2026, 10:44 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Albuterol for Status Asthmaticus

NCT02966184
View directory record Official record
Conditions
Status Asthmaticus
Interventions
preservative free albuterol
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
5 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02275052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

NCT01068600
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
54
States / cities
Anniston, Alabama • Jasper, Alabama • Glendale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma

NCT00667407
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol 1.25 mg, Racemic Albuterol Sulfate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
28
States / cities
Hoover, Alabama • Montgomery, Alabama • Encinitas, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

NCT03364608
View directory record Official record
Conditions
Asthma
Interventions
AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol

NCT01263197
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, albuterol, propranolol, placebo for LY2216684, placebo for albuterol, placebo for propranolol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 4 Interventional

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

NCT00144911
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
85
States / cities
Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

NCT02573870
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

NCT00268723
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
Levalbuterol tartrate HFA MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Denver, Colorado • Burke, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Not applicable Interventional Results available

HHHFA in COPD Patients, With Chronic Bronchitis

NCT03959982
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
HHHFA Device, Spirometry, 6-minute walk, CT scan, Medical Research Council dyspnea scale (MRC), St. George's Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), Pittsburgh Sleep Quality Index (PSQI), CASA-Q, Spirehealth Tag Device
Device · Diagnostic Test · Other
Lead sponsor
Spyridon Fortis
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT00808288
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
Interventions
PF- 00610355, Placebo, Salmeterol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Fairhope, Alabama • San Diego, California • Spring Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 24, 2026, 10:44 AM EDT